A DECADES STUDIES ON THE IMMUNOTARGETING THERAPY OF HEPATOCELLULAR-CARCINOMA

A decade's studies of the immunotargeting therapy of hepatocellular ca rcinoma (HCC) are summarized. Eight carriers have been studied: anti-h uman HCC ferritin antibody (FtAb), L subunit ferritin monoclonal antib ody (L-Ft MoAb), H-Ft MoAb, anti-human HCC MoAbs (Hepama-1, and HCMP-1 ), anti alpha fetoprotein Ab (AFP-Ab), AFP-MoAb, anti-hepatitis B-x an tigen MoAb (HBxAg MoAb) and fragments from L-Ft MoAb and HCMP-1 MoAb. The results of immunohistochemistry, experimental and clinical radioim munoimaging (RAII), experimental radioimmunotherapy (RAM, clinical RAI T in 75 patients with HCC using I-131 Ft Ab (n = 43) and I-131 Hepama- 1 MoAb (n = 32), anti-antibody and pharmacokinetics, pathological stud y of surgical specimens after RAIT, comparison of cocktail MoAbs and s ingle MoAb, and chemoimmunoconjugates were delineated. It is suggested that RAIT remained one of the approaches to cytoreduction and sequent ial resection of unresectable HCC, particularly when integrated in the multimodality treatment of HCC.